Relmada Therapeutics Inc - Asset Resilience Ratio
Relmada Therapeutics Inc (RLMD) has an Asset Resilience Ratio of 95.22% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Relmada Therapeutics Inc total assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Relmada Therapeutics Inc's Asset Resilience Ratio has changed over time. See Relmada Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Relmada Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Relmada Therapeutics Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $89.51 Million | 95.22% |
| Total Liquid Assets | $89.51 Million | 95.22% |
Asset Resilience Insights
- Very High Liquidity: Relmada Therapeutics Inc maintains exceptional liquid asset reserves at 95.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Relmada Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Relmada Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Relmada Therapeutics Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Relmada Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 95.22% | $89.51 Million | $94.00 Million | +5.62pp |
| 2024-12-31 | 89.60% | $41.05 Million | $45.82 Million | -4.95pp |
| 2023-12-31 | 94.55% | $92.23 Million | $97.55 Million | +1.07pp |
| 2022-12-31 | 93.47% | $142.93 Million | $152.91 Million | +18.49pp |
| 2021-12-31 | 74.99% | $167.47 Million | $223.33 Million | -21.97pp |
| 2020-12-31 | 96.96% | $114.60 Million | $118.19 Million | +28.52pp |
| 2019-12-31 | 68.44% | $80.16 Million | $117.14 Million | -- |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more